mitoquinone: Clinical Trials

18 trials of mitoquinone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 recruiting, 3 terminated, 2 not yet recruiting. 18 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 218Completed 8, Recruiting 3, Terminated 3, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1
Phase 13Completed 2, Terminated 1
Phase 31Recruiting 1

Follow mitoquinone: new trials by email Literature Review of mitoquinone trials Research Report on mitoquinone

Trials (filtered) newest first · largest first

All 18 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MitoQ Supplementation for Microvascular Health and Stroke Recovery
MitoQ, Placebo - Stroke, Stroke Recurrence
Phase 2Not yet recruitingMedical College of Wisconsin502027-01-012026-11-16
Efficacy and Safety of MitoQ in Improving Cancer Cachexia
MitoQ (mitoquinol mesylate) - Cancer Cachexia (CC), Cancer Patients With Solid Tumors
Phase 2Not yet recruitingThe First Affiliated Hospital of Xinxiang Medical College202026-10-102026-09-23
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
MitoQ, Placebo - Ulcerative Colitis
Phase 2WithdrawnUniversity of Edinburgh2025-09-012026-01-09
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Mitoquinone Mesylate, Placebo capsule - Frailty, Mild Cognitive Impairment
Phase 2RecruitingUConn Health602024-10-072026-08-12
Effects of an Antioxidant Supplement on Blood Vessel Health
MitoQ, Placebo, MitoTempo - Healthy
Phase 2RecruitingUniversity of Georgia602024-07-012024-12-09
ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
Astaxanthin, Protandim, Melatonin - Amyotrophic Lateral Sclerosis ALS
Phase 2CompletedDuke University502024-06-122026-10-27
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
MitoQ, Placebo - Schizophrenia and Related Disorders, Mitochondrial Alteration
Phase 2 / Phase 3RecruitingMclean Hospital1002024-06-012025-09-25
Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome
MitoQ (mitoquinol mesylate), Placebo - Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Phase 2TerminatedIman Al-Naggar, PhD202024-04-032026-05-01
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Mitoquinone/mitoquinol mesylate, Placebo - SARS-CoV Infection, COVID-19
Phase 2CompletedUniversity of Texas Southwestern Medical Center1222024-03-012026-09-21
Examining the Effects of Mitochondrial Oxidative Stress in DCM
MitoQ Compound, Placebo - Dilated Cardiomyopathy
Phase 2CompletedImperial College London532022-07-262025-09-18
MARVEL: Mitochondrial Anti-oxidant Therapy to Resolve Inflammation in Ulcerative Colitis
MitoQ, Placebo - Ulcerative Colitis Flare
Phase 2Active not recruitingUniversity of Edinburgh792022-05-312026-01-13
An Open Label Study in Adults to Test the Efficacy of Mitoquinone/Mitoquinol Mesylate to Prevent Severe Viral Illness
Mitoquinone/mitoquinol mesylate - Respiratory Viral Infection, Antiviral Treatment
Phase 1 / Phase 2CompletedUniversity of California, Los Angeles802022-04-282025-12-16
Mitochondrial-targeted Antioxidant Supplementation for Improving Age-related Vascular Dysfunction in Humans
MitoQ, Placebo - Aging
Phase 2CompletedUniversity of Colorado, Boulder1122021-04-022026-08-05
MitoQ for Fatigue in Multiple Sclerosis (MS)
20 mg MitoQ, Placebo, 40mg of MitoQ - Multiple Sclerosis, Fatigue
Phase 1 / Phase 2CompletedVA Office of Research and Development452020-04-012026-04-24
MitoQ for Fatigue in Multiple Sclerosis
Mitoquinone, Placebo - Multiple Sclerosis, Fatigue
Phase 1 / Phase 2TerminatedOregon Health and Science University92018-09-152023-04-05
A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
Mitoquinone mesylate, Placebo - Non-alcoholic Fatty Liver Disease
Phase 2TerminatedAntipodean Pharmaceuticals, Inc.1102010-11-012011-06-01
Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C
Mitoquinone mesylate (MitoQ) - Chronic Hepatitis C
Phase 2CompletedAntipodean Pharmaceuticals, Inc.302007-03-012008-08-14
A Trial of MitoQ for the Treatment of People With Parkinson's Disease
MitoQ - Parkinson's Disease
Phase 2CompletedAntipodean Pharmaceuticals, Inc.1282006-05-012010-07-21

Conditions studied

COVID-19 (2)  ·  Cognitive Dysfunction (2)  ·  Fatigue (2)  ·  Multiple Sclerosis (2)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Cardiomyopathy, Dilated (1)  ·  Cardiovascular Diseases (1)  ·  Colitis, Ulcerative (1)  ·  Frailty (1)  ·  Hepatitis C (1)  ·  Hepatitis C, Chronic (1)  ·  Hypertension (1)  ·  Lower Urinary Tract Symptoms (1)  ·  Metabolic Syndrome (1)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

Antipodean Pharmaceuticals, Inc. (3)  ·  University of Edinburgh (2)  ·  Duke University (1)  ·  Iman Al-Naggar, PhD (1)  ·  Imperial College London (1)  ·  Mclean Hospital (1)  ·  Medical College of Wisconsin (1)  ·  Oregon Health and Science University (1)  ·  The First Affiliated Hospital of Xinxiang Medical College (1)  ·  UConn Health (1)  ·  University of California, Los Angeles (1)  ·  University of Colorado, Boulder (1)  ·  University of Georgia (1)  ·  University of Texas Southwestern Medical Center (1)  ·  VA Office of Research and Development (1)

Countries

United States (11)  ·  United Kingdom (4)  ·  New Zealand (2)  ·  Australia (1)  ·  Switzerland (1)

Top investigators

Barry J Snow, MD (1)  ·  Brian Halliday, MBChB PhD (1)  ·  Chris Day, MD, PhD (1)  ·  David Wilson, MD (1)  ·  Dost Ongur, MD, PhD (1)  ·  Douglas R Seals (1)  ·  Edward J Gane, MBChB (1)  ·  Iman M Al-Naggar, PhD (1)  ·  Matthew Durand, PhD (1)  ·  Oh Sung Kwon, PhD (1)  ·  Theodoros Kelesidis, MD PHD (1)  ·  Theodoros Kelesidis, MD, PHD, Msc (1)  ·  Vijayshree Yadav, MBBS (1)  ·  Vijayshree Yadav, MD (1)

Results publications

PMID 20492507, PMID 36187760, PMID 38471990, PMID 40603760, PMID 41264372

NIH funding

K01AG080164 (1), P30AG067988 (1), R01AG066730 (1)